Skip to main content
H

HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 002900 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,257 across all filing types
Latest filing 2026-04-27 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002900

About HARBIN MEDISAN PHARMACEUTICAL CO.,LTD.

https://www.medisan.com.cn

Harbin Medisan Pharmaceutical Co., Ltd. focuses on the research, development, production, and distribution of various medicinal formulations. Its product portfolio encompasses small-volume injections, large-volume injections, lyophilized powder for injection, and solid oral dosage forms such as tablets and capsules. The company specializes in therapeutic categories including cardiovascular and cerebrovascular health, anti-infectives, and gastrointestinal treatments. Utilizing advanced manufacturing technologies and adhering to rigorous quality management systems, the organization aims to provide high-quality therapeutic solutions. Its operations are supported by modern production facilities and a commitment to technical innovation in drug delivery and formulation.

Recent filings

Filing Released Lang Actions
2025年度独立董事述职报告-曾国林（已离任）
Governance Information Classification · 1% confidence The document is a standalone annual performance report by an independent director (“独立董事述职报告”), detailing board attendance, committee work, governance oversight and independent duties. It does not present financial results (so it’s not an Annual Report, IR or ER), nor is it merely a notice of a publication or voting results. It focuses on corporate governance and board practices, aligning with the Governance Information category (Code: CGR).
2026-04-27 Chinese
2025年度财务决算报告
Annual Report Classification · 1% confidence The document is the full 2025 audited annual financial results of Harbin Sanlian Pharmaceutical Co., Ltd., including consolidated balance sheet, income statement, cash flows, notes on major changes and an unqualified auditor’s report. It is a comprehensive yearly report covering all financial performance rather than a brief announcement or presentation. This matches the definition of an Annual Report (10-K). FY 2025
2026-04-27 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 1% confidence The document is an official announcement by Harbin Sanlian Pharmaceutical Co. regarding changes to its accounting policies following new accounting standard interpretations from the Ministry of Finance. It is not a full financial report (Annual Report or Interim Report), nor an earnings release or investor presentation, and does not fit into any specialized category such as dividends, M&A, or board changes. It is a regulatory disclosure filed with the stock exchange, so it falls under the general “Regulatory Filings” category (RNS).
2026-04-27 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 1% confidence The document title and content clearly identify it as the company’s 2026 first quarter report (“2026年第一季度报告”). It includes substantive financial statements (balance sheet, income statement, cash flow statement), key accounting data, financial indicators, and shareholder information – all consistent with an interim/quarterly report rather than a brief announcement or an earnings release. Therefore, it should be classified as an Interim / Quarterly Report. Q1 2026
2026-04-27 Chinese
2025年度营业收入扣除事项专项核查报告-上会师报字(2026)第8041号
Audit Report / Information Classification · 1% confidence The document is a standalone auditor’s “专项核查报告” (special inspection report) issued by an accounting firm on the company’s 2025 revenue deduction matters. It is not the full annual report or just an announcement; it constitutes an independent audit-related opinion and supporting schedules. This fits the “Audit Report / Information (AR)” category.
2026-04-27 Chinese
2025年年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 1% confidence The document is a standalone summary table detailing related‐party non-operating fund occupancy and intercompany balances for the 2025 fiscal year. It is not an announcement of a report’s publication, nor does it fit into any narrative report type (e.g., Annual Report, Earnings Release). It contains detailed statutory disclosure data but does not correspond to any specialized category (e.g., CAP, DIRS, DIV). Therefore, under our taxonomy it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-27 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.